TP53 and neoplasm: This raises some interesting hypotheses: (1) CDK9 inhibition promotes p53-specific signaling and tumor suppression in WT p53 expressing NSCLCs; and (2) mutant p53 expressing NSCLCs respond to CDK9 inhibition in a p53-independent manner.